A new report showing “research funding for four key HIV prevention options – preventive vaccines, microbicides, PrEP and operations research related to medical male circumcision” – increased in 2010 compared with 2009 “is certainly good news, but we cannot rest on our laurels,” Margaret McGlynn, president and CEO of the International AIDS Vaccine Initiative, Zeda Rosenberg, CEO of the International Partnership for Microbicides, and Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, write in a post on the Global Health Magazine’s blog. “Funding data in recent years speak to the commitment of donors to this crucial effort. However, capitalizing on the current momentum in HIV prevention R&D will require both sustained and increased commitment,” they conclude (7/19).